Try our mobile app

General information

Country: UNITED STATES

Sector: Drug Manufacturers — General

Categories: @vaccine-makers   

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Website: jnj.com


  • Good financial results growth rate 42.8% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (16.4%)
  • Dividend yield for the last twelve months 2.8%
  • Free cash flow yield -2.0% (LTM)
  • Share price is 31.3% higher than minimum and 3.7% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (13.3x vs
    )
  • Fundamental value created in LTM (estimate)

Key Financials (Download financials)

Ticker: JNJ
Share price, USD:  (-0.2%)186.57
year average price 162.01  


year start price 155.47 2024-11-10

min close price 142.06 2025-01-10

max close price 193.72 2025-10-20

current price 186.57 2025-11-09
Common stocks: 2 631 399 832

Dividend Yield:  2.8%
FCF Yield LTM: -2.0%
EV / LTM EBITDA: 13.3x
EV / EBITDA annualized: 14.0x
Last revenue growth (y/y):  +6.8%
Last growth of EBITDA (y/y):  +78.8%
Historical revenue growth:  +2.3%
Historical growth of EBITDA:  +30.5%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 490 940
Net Debt ($m): 27 233
EV (Enterprise Value): 518 173
EBITDA LTM ($m): 38 890
EV / LTM EBITDA: 13.3x
Price to Book: 7.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-11-07seekingalpha.com

Johnson & Johnson: Dividends Don't Lie

2025-11-06prnewswire.com

DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma

2025-11-06reuters.com

US FDA expands use of J&J's Caplyta as add-on depression drug

2025-10-30zacks.com

Here's Why Johnson & Johnson (JNJ) is a Strong Value Stock

2025-10-28globenewswire.com

Levin Papantonio Announces Jury Awards $20 Million Verdict in Talc Mesothelioma Case Casaretto Estate v. Johnson & Johnson

2025-10-27zacks.com

Here's Why Johnson & Johnson (JNJ) is a Strong Momentum Stock

2025-10-27prnewswire.com

TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn's disease at two years

2025-10-24prnewswire.com

Published in The Lancet: Nipocalimab significantly decreased Sjögren's disease (SjD) activity and severity through substantial reduction in Sjögren's-related autoantibodies

2025-10-22businesswire.com

Johnson & Johnson to Participate in the 7th Annual Wolfe Research Healthcare Conference

2025-10-22forbes.com

Johnson & Johnson Stock To $134?
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data